Madrigal Pharmaceuticals (MDGL) Earnings Date, Estimates & Call Transcripts $245.00 +11.84 (+5.08%) (As of 12:59 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 4EstimatedActual EPS (Aug. 7) -$7.10 Beat By $0.45 Consensus EPS (Aug. 7) -$7.55 Conference Call TranscriptConference Call AudioEarnings Press Release Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueMDGL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MDGL Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now. Madrigal Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243($6.66)($5.82)($6.17)Q2 20243($8.36)($5.63)($7.16)Q3 20243($8.45)($4.91)($6.70)Q4 20243($6.18)($3.22)($4.78)FY 202412($29.65)($19.58)($24.80)MDGL Earnings Date and InformationMadrigal Pharmaceuticals last released its earnings data on August 7th, 2024. The biopharmaceutical company reported ($7.10) EPS for the quarter, beating the consensus estimate of ($7.55) by $0.45. The business had revenue of $14.64 million for the quarter, compared to analysts' expectations of $4.25 million. Its quarterly revenue was up 146280.0% on a year-over-year basis. Madrigal Pharmaceuticals has generated ($23.09) earnings per share over the last year (($23.09) diluted earnings per share). Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($27.67) to ($17.76) per share. Madrigal Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off prior year's report dates.Read More Madrigal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/4/2024(Estimated)------- 8/7/2024Q2 2024($7.55)($7.10)+$0.45($7.10)$4.25 million$14.64 million 5/7/2024Q1 2024($6.06)($7.38)($1.32)($7.38)-- 2/28/2024Q4 2023($5.26)($5.68)($0.42)($5.68)-- 11/6/2023Q3 2023($4.90)($5.34)($0.44)($5.34)-- 8/8/2023Q2 2023($4.59)($4.69)($0.10)($4.69)-- 5/9/2023Q1 2023($4.78)($4.23)+$0.55($4.23)-- This Crypto Is Set to Explode in September (Ad)With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now. 2/23/2023Q4 2022($4.61)($4.98)($0.37)($4.98)-- 11/3/2022Q3 2022($4.05)($4.75)($0.70)($4.75)-- 8/4/2022Q2 2022($3.76)($4.14)($0.38)($4.14)-- 5/9/2022Q1 2022($3.75)($3.36)+$0.39($3.36)-- 2/24/2022Q4 2021($3.92)($3.78)+$0.14($3.78)-- 11/4/2021Q3 2021($3.87)($3.79)+$0.08($3.79)-- 8/5/2021Q2 2021($3.58)($3.72)($0.14)($3.72)-- 5/6/2021Q1 2021($3.85)($3.32)+$0.53($3.32)-- 2/25/2021Q4 2020($3.98)($3.82)+$0.16($3.82)--11/5/2020Q3 2020($3.37)($3.75)($0.38)($3.75)-- 8/6/2020Q2 2020($2.43)($3.18)($0.75)($3.18)--5/7/2020Q1 2020($1.94)($2.34)($0.40)($2.34)--2/26/2020Q4 2019($1.67)($1.80)($0.13)($1.80)--11/6/2019Q3($1.42)($1.39)+$0.03($1.39)-- Madrigal Pharmaceuticals Earnings - Frequently Asked Questions When is Madrigal Pharmaceuticals's earnings date? Madrigal Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates. Learn more on MDGL's earnings history. Did Madrigal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Madrigal Pharmaceuticals (NASDAQ:MDGL) reported ($7.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($7.55) by $0.45. Learn more on analysts' earnings estimate vs. MDGL's actual earnings. How can I listen to Madrigal Pharmaceuticals's earnings conference call? The conference call for Madrigal Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Madrigal Pharmaceuticals's conference call transcript? The conference call transcript for Madrigal Pharmaceuticals's latest earnings report can be read online. Read Transcript How much profit does Madrigal Pharmaceuticals generate each year? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded net income of -$373.63 million. MDGL has generated -$23.09 earnings per share over the last four quarters. What is Madrigal Pharmaceuticals's EPS forecast for next year? Madrigal Pharmaceuticals's earnings are expected to grow from ($27.67) per share to ($17.76) per share in the next year. More Earnings Resources from MarketBeat Related Companies: RCKT Earnings Date YMAB Earnings Date GBIO Earnings Date BMRN Earnings Date UTHR Earnings Date INCY Earnings Date NBIX Earnings Date EXAS Earnings Date RGEN Earnings Date EXEL Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:MDGL) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Madrigal Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
